Fracture Risk in Men With Congestive Heart Failure. Risk Reduction With Spironolactone

Laura D. Carbone, Jessica D. Cross, Syed Raza, Andrew J. Bush, Robert J. Sepanski, Saurabh Dhawan, Bilal Q. Khan, Malini Gupta, Khurram Ahmad, Rami Khouzam, Dwight Dishmon, Joseph P. Nesheiwat, Mohammad A. Hajjar, Waqas A. Chishti, Wael Nasser, Mehwish Khan, Catherine Womack, Tara Cho, Ashley R. Haskin, Karl Weber

Research output: Contribution to journalArticle

60 Citations (Scopus)

Abstract

Objectives: The purpose of this study was to determine whether spironolactone use is associated with fractures in men with congestive heart failure (CHF). Background: In rats with aldosteronism, spironolactone preserves skeletal strength. However, in humans, the relationship of spironolactone to fractures is not known. Methods: The medical records of all male patients with CHF from 1999 to 2005 treated at the Veterans Affairs Medical Center, Memphis, Tennessee, were reviewed (n = 4,735). Odds ratios with 95% confidence intervals of having a fracture associated with spironolactone use were estimated using conditional logistic regression. Results: We identified 167 cases with a single-incident fracture and matched these by age and race to 668 control subjects without fractures. After adjustment for covariates, spironolactone use was inversely associated with total fracture (odds ratio: 0.575; 95% confidence interval: 0.346 to 0.955, p = 0.0324). Conclusions: The use of spironolactone is inversely associated with fractures in men with CHF.

Original languageEnglish (US)
Pages (from-to)135-138
Number of pages4
JournalJournal of the American College of Cardiology
Volume52
Issue number2
DOIs
StatePublished - Jul 8 2008

Fingerprint

Spironolactone
Risk Reduction Behavior
Heart Failure
Odds Ratio
Confidence Intervals
Hyperaldosteronism
Veterans
Medical Records
Logistic Models

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Cite this

Fracture Risk in Men With Congestive Heart Failure. Risk Reduction With Spironolactone. / Carbone, Laura D.; Cross, Jessica D.; Raza, Syed; Bush, Andrew J.; Sepanski, Robert J.; Dhawan, Saurabh; Khan, Bilal Q.; Gupta, Malini; Ahmad, Khurram; Khouzam, Rami; Dishmon, Dwight; Nesheiwat, Joseph P.; Hajjar, Mohammad A.; Chishti, Waqas A.; Nasser, Wael; Khan, Mehwish; Womack, Catherine; Cho, Tara; Haskin, Ashley R.; Weber, Karl.

In: Journal of the American College of Cardiology, Vol. 52, No. 2, 08.07.2008, p. 135-138.

Research output: Contribution to journalArticle

Carbone, LD, Cross, JD, Raza, S, Bush, AJ, Sepanski, RJ, Dhawan, S, Khan, BQ, Gupta, M, Ahmad, K, Khouzam, R, Dishmon, D, Nesheiwat, JP, Hajjar, MA, Chishti, WA, Nasser, W, Khan, M, Womack, C, Cho, T, Haskin, AR & Weber, K 2008, 'Fracture Risk in Men With Congestive Heart Failure. Risk Reduction With Spironolactone', Journal of the American College of Cardiology, vol. 52, no. 2, pp. 135-138. https://doi.org/10.1016/j.jacc.2008.03.039
Carbone, Laura D. ; Cross, Jessica D. ; Raza, Syed ; Bush, Andrew J. ; Sepanski, Robert J. ; Dhawan, Saurabh ; Khan, Bilal Q. ; Gupta, Malini ; Ahmad, Khurram ; Khouzam, Rami ; Dishmon, Dwight ; Nesheiwat, Joseph P. ; Hajjar, Mohammad A. ; Chishti, Waqas A. ; Nasser, Wael ; Khan, Mehwish ; Womack, Catherine ; Cho, Tara ; Haskin, Ashley R. ; Weber, Karl. / Fracture Risk in Men With Congestive Heart Failure. Risk Reduction With Spironolactone. In: Journal of the American College of Cardiology. 2008 ; Vol. 52, No. 2. pp. 135-138.
@article{228d249a6f0b4c2286cdf2ff366c7fca,
title = "Fracture Risk in Men With Congestive Heart Failure. Risk Reduction With Spironolactone",
abstract = "Objectives: The purpose of this study was to determine whether spironolactone use is associated with fractures in men with congestive heart failure (CHF). Background: In rats with aldosteronism, spironolactone preserves skeletal strength. However, in humans, the relationship of spironolactone to fractures is not known. Methods: The medical records of all male patients with CHF from 1999 to 2005 treated at the Veterans Affairs Medical Center, Memphis, Tennessee, were reviewed (n = 4,735). Odds ratios with 95{\%} confidence intervals of having a fracture associated with spironolactone use were estimated using conditional logistic regression. Results: We identified 167 cases with a single-incident fracture and matched these by age and race to 668 control subjects without fractures. After adjustment for covariates, spironolactone use was inversely associated with total fracture (odds ratio: 0.575; 95{\%} confidence interval: 0.346 to 0.955, p = 0.0324). Conclusions: The use of spironolactone is inversely associated with fractures in men with CHF.",
author = "Carbone, {Laura D.} and Cross, {Jessica D.} and Syed Raza and Bush, {Andrew J.} and Sepanski, {Robert J.} and Saurabh Dhawan and Khan, {Bilal Q.} and Malini Gupta and Khurram Ahmad and Rami Khouzam and Dwight Dishmon and Nesheiwat, {Joseph P.} and Hajjar, {Mohammad A.} and Chishti, {Waqas A.} and Wael Nasser and Mehwish Khan and Catherine Womack and Tara Cho and Haskin, {Ashley R.} and Karl Weber",
year = "2008",
month = "7",
day = "8",
doi = "10.1016/j.jacc.2008.03.039",
language = "English (US)",
volume = "52",
pages = "135--138",
journal = "Journal of the American College of Cardiology",
issn = "0735-1097",
publisher = "Elsevier USA",
number = "2",

}

TY - JOUR

T1 - Fracture Risk in Men With Congestive Heart Failure. Risk Reduction With Spironolactone

AU - Carbone, Laura D.

AU - Cross, Jessica D.

AU - Raza, Syed

AU - Bush, Andrew J.

AU - Sepanski, Robert J.

AU - Dhawan, Saurabh

AU - Khan, Bilal Q.

AU - Gupta, Malini

AU - Ahmad, Khurram

AU - Khouzam, Rami

AU - Dishmon, Dwight

AU - Nesheiwat, Joseph P.

AU - Hajjar, Mohammad A.

AU - Chishti, Waqas A.

AU - Nasser, Wael

AU - Khan, Mehwish

AU - Womack, Catherine

AU - Cho, Tara

AU - Haskin, Ashley R.

AU - Weber, Karl

PY - 2008/7/8

Y1 - 2008/7/8

N2 - Objectives: The purpose of this study was to determine whether spironolactone use is associated with fractures in men with congestive heart failure (CHF). Background: In rats with aldosteronism, spironolactone preserves skeletal strength. However, in humans, the relationship of spironolactone to fractures is not known. Methods: The medical records of all male patients with CHF from 1999 to 2005 treated at the Veterans Affairs Medical Center, Memphis, Tennessee, were reviewed (n = 4,735). Odds ratios with 95% confidence intervals of having a fracture associated with spironolactone use were estimated using conditional logistic regression. Results: We identified 167 cases with a single-incident fracture and matched these by age and race to 668 control subjects without fractures. After adjustment for covariates, spironolactone use was inversely associated with total fracture (odds ratio: 0.575; 95% confidence interval: 0.346 to 0.955, p = 0.0324). Conclusions: The use of spironolactone is inversely associated with fractures in men with CHF.

AB - Objectives: The purpose of this study was to determine whether spironolactone use is associated with fractures in men with congestive heart failure (CHF). Background: In rats with aldosteronism, spironolactone preserves skeletal strength. However, in humans, the relationship of spironolactone to fractures is not known. Methods: The medical records of all male patients with CHF from 1999 to 2005 treated at the Veterans Affairs Medical Center, Memphis, Tennessee, were reviewed (n = 4,735). Odds ratios with 95% confidence intervals of having a fracture associated with spironolactone use were estimated using conditional logistic regression. Results: We identified 167 cases with a single-incident fracture and matched these by age and race to 668 control subjects without fractures. After adjustment for covariates, spironolactone use was inversely associated with total fracture (odds ratio: 0.575; 95% confidence interval: 0.346 to 0.955, p = 0.0324). Conclusions: The use of spironolactone is inversely associated with fractures in men with CHF.

UR - http://www.scopus.com/inward/record.url?scp=45849120256&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=45849120256&partnerID=8YFLogxK

U2 - 10.1016/j.jacc.2008.03.039

DO - 10.1016/j.jacc.2008.03.039

M3 - Article

VL - 52

SP - 135

EP - 138

JO - Journal of the American College of Cardiology

JF - Journal of the American College of Cardiology

SN - 0735-1097

IS - 2

ER -